Interdigit and Njex proceed with European alliance
This article was originally published in Clinica
Swiss company Interdigit (Nyon) is pushing ahead with plans to market implanting technology from Njex Medical Systems in Europe. The small, sterile Njex implants are well suited for controlled release and long-term targeted delivery implant treatments, says the company from Industry, California. The cost-effective procedures allowed by the technology are faster and simpler, and require "little or no surgical skill" in that they can implanted under outpatient conditions. The technology is expected to enhance treatment methods for a host of existing and emerging products, the companies say.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.